Anbogen Therapeutics Begins FDA-Approved Trial for New Cancer Treatment
Anbogen Therapeutics has exciting news! The U.S. Food and Drug Administration (FDA) has granted approval for their Investigational New Drug (IND) application concerning ABT-301. This approval allows the biopharmaceutical company to initiate a Phase 1/2 clinical trial combining ABT-301 with two other existing therapies for patients facing metastatic colorectal cancer (mCRC).
Overview of the Phase 1/2 Clinical Trial
The study is designed to enroll 66 participants suffering from proficient mismatch repair (pMMR) or non-microsatellite instability-high (non-MSI-H) mCRC. This open-label, multi-center international study aims to evaluate both the safety and preliminary efficacy of the triplet therapy. While specific enrollment locations include various international sites, Anbogen is committed to reaching a broad spectrum of patients.
The Triplet Therapy Explained
In this trial, ABT-301 will be combined with tislelizumab and bevacizumab. Tislelizumab is a PD-1 monoclonal antibody provided by BeOne Medicines, providing an innovative approach to cancer treatment. Together, these therapies are expected to produce better results compared to traditional treatments alone.
Mechanism and Benefits of ABT-301
ABT-301 is notably an oral HDAC1/2/3 inhibitor, and preclinical studies have shown it to significantly enhance the immune response. By increasing the activity of CD8+ cytotoxic T cells and improving antigen presentation, it effectively modifies the tumor microenvironment. This novel mechanism is essential as it aims to convert traditionally “cold tumors” into “hot tumors,” enhancing their responsiveness to immune checkpoint inhibitors.
Assessment of Previous Trials
In an earlier Phase 1 trial, ABT-301 was tested as a monotherapy involving 23 volunteers, where it demonstrated a promising safety profile. Importantly, there were no signs of neutropenia or cardiac toxicity, adverse effects frequently seen in other HDAC inhibitors, which strengthens its compatibility for combination therapy use.
Market Potential and Impact
About 95% of patients with mCRC fall into the categories of pMMR or non-MSI-H tumors, labeled as “cold tumors,” which tend to respond poorly to conventional immunotherapies. Statistics reveal that only a small fraction, roughly 5%, of patients with deficient mismatch repair (dMMR) or microsatellite instability-high (MSI-H) tumors benefit from existing immune checkpoint inhibitors. According to industry estimates, there are about 370,000 new diagnoses of pMMR/non-MSI-H patients each year across significant markets, indicating a massive potential market size that could reach USD 9 billion.
Milestones in Development
Anbogen is excited about the FDA's IND approval, marking a pivotal point in the progress of ABT-301. This crucial development underscores the promising safety profile of the triplet therapy and paves the way for advancing clinical applications. The company focuses on serving the majority of patients who have encountered poor responses to previous immunotherapy options, aiming to introduce an innovative treatment approach.
Future Growth and Strategic Initiatives
As Anbogen moves forward, the strategic focus remains not only on the clinical development of ABT-301 but also on exploring global licensing opportunities and partnerships. These initiatives are intended to accelerate market entry and commercialization of their therapies. Additionally, Anbogen is activating their Series B fundraising to attract partners who share a commitment to forward-thinking cancer treatments and their global outreach.
About Anbogen Therapeutics
Anbogen Therapeutics stands out as a clinical-stage biotechnology organization dedicated to creating precision oncology therapies. These efforts are rooted in improving the lives of cancer patients everywhere. The company has two flagship assets:
ABT-301, an innovative HDAC1/2/3 inhibitor, is geared towards enhancing the tumor microenvironment while boosting immune responses. Meanwhile, ABT-501, a novel Peptide Drug Conjugate (PDC), effectively targets LHRH-receptor tumors through a proprietary delivery mechanism, showcasing strong efficacy in models of triple-negative breast cancer with wider implications for various cancer types.
Frequently Asked Questions
What is the purpose of the ABT-301 trial?
The trial aims to evaluate the safety and preliminary efficacy of the triplet therapy combining ABT-301, tislelizumab, and bevacizumab for advanced colorectal cancer.
How many patients are expected to participate in the trial?
The study plans to enroll approximately 66 patients diagnosed with metastatic colorectal cancer.
What does ABT-301 target?
ABT-301 targets HDAC1/2/3 and is designed to improve immune responses in cold tumors, enhancing their effectiveness against cancer.
What have previous trials revealed about ABT-301?
Earlier trials showed that ABT-301 did not produce common side effects observed in other HDAC inhibitors, presenting it as a safer option for combination therapy.
What is Anbogen's broader mission?
Anbogen Therapeutics is committed to developing precise oncology therapies that significantly improve the outcomes and quality of life for cancer patients worldwide.
